Cardlytics Inc (CDLX)
NASDAQCommunication ServicesAdvertising AgenciesSnapshot 2026-09-09
$4.27+14.17%
Close 2026-09-09 · 1-day change
NASDAQCommunication ServicesAdvertising AgenciesSnapshot 2026-09-09
Intact: The reason to own it still holds.
Cardlytics aims for $37.5M revenue next quarter. They plan a 1-for-10 reverse stock split. The company works to meet Nasdaq listing rules. Recent earnings beats show some progress.
Cardlytics is losing money and sales are expected to drop 16%. The stock price fell 64% from its high. Leadership changes and Nasdaq delisting risk hurt confidence.
The market expects about 16% revenue decline next year. Our fair value is near $18.8, reflecting this weak outlook. We see risk in the turnaround progress.
Breaks if: Reverse stock split not completed by mid-2026
Breaks if: EPS loss worsens beyond -$1.1 next quarter
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
CDLX represents a speculative growth investment with a medium confidence level. The current thesis state is cautious due to recent earnings misses and mixed management execution.
The market currently prices CDLX as cheap compared to its peers, with an expectations gap indicating that the market anticipates lower performance. However, the valuation is justified given the recent financial struggles.
Management is focused on achieving sequential growth and self-sustainability, as evidenced by recent revenue and EBITDA improvements. However, the decline in monthly qualified users raises concerns about user engagement and overall growth potential.
The long-term thesis hinges on the performance of sector bellwethers like OMC, TTD, and MGNI, which could influence CDLX's momentum. Additionally, management's ability to improve user engagement and maintain growth will be critical.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company expects revenue growth in Q3 2026. It also aims for positive adjusted EBITDA and better margins. These factors support a more favorable outlook. There are no new threats to the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Fail to meet Nasdaq minimum bid price within 12 months
Breaks if: Revenue falls below $35 million next quarter
In the next 1 to 3 years, CDLX's performance will depend on both sector trends and internal execution. Not investment advice.